We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Cellular RNAs are bound by a variety of RNA binding proteins. Identifying the targets of these proteins and determining the functional consequences of RNA-protein interactions have been the focus of intensive research. Tuschl and colleagues now present a method that enables efficient isolation of RNAs bound to a specific protein and high-resolution mapping(More)
383 fibrosis. The curse of neurodegenerative disorders again claimed two experimental drugs: Medivation’s Dimebon and Trophos’ Olesoxime. Shire ditched its US marketing application for Replagal, a human glucocerebrosidase available in Europe since 2001, after the FDA required further efficacy trials. The rate of US Food and Drug Administration (FDA)(More)
volume 28 number 3 march 2010 nature biotechnology therapeutic targets, and why are they better than our current favorites? After all, it can be argued that industry is already awash in seemingly attractive targets and early drug discovery projects. Unfortunately, until a large number of cancer genomes is sequenced and functional mutations are discovered,(More)
  • 1